Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Fresnillo reports declines in gold, silver production

(Sharecast News) - Fresnillo reported a 9.7% quarter-on-quarter decline in attributable silver production to 12.4 million ounces for the first quarter of the year on Wednesday, including output from the Silverstream contract. The FTSE 100 precious metals miner said the drop was mainly due to lower ore grades and processing volumes at Saucito, the end of mining at San Julián DOB, and reduced throughput at San Julián Veins.

Compared with the same period last year, silver production fell 8.4%, despite higher grades at Fresnillo and increased Silverstream contributions.

Gold production totalled 156,100 ounces in the quarter, a 23.5% fall from the previous quarter due to lower grades and reduced ore volumes at key assets including Herradura, Saucito, and Ciénega.

However, gold output rose 10.8% year-on-year, supported by higher grades, throughput and recovery at Herradura.

By-product lead and zinc production also declined sequentially, falling 10.9% and 12.8% respectively, as grades and volumes weakened across multiple sites and San Julián DOB ceased operations.

Compared to the first quarter of 2024, lead production was flat while zinc output declined, largely reflecting reduced contribution from San Julián and lower volumes at Fresnillo.

The company reaffirmed its full-year production guidance, expecting silver output between 49.0 and 56.0 million ounces, and gold production between 525,000 and 580,000 ounces.

Lead and zinc guidance was also maintained, at 56,000 to 62,000 tonnes and 93,000 to 103,000 tonnes respectively.

Fresnillo said it was still targeting total silver equivalent production of 91 million to 102 million ounces for the year.

The miner said its safety performance remained a top priority, with ongoing efforts to reinforce training and adherence to protocols as part of its zero fatalities objective.

It added that its production outlook for 2026 and 2027 remains unchanged.

"We have started 2025 in line with our expectations, delivering a stable operating performance and maintaining the momentum we achieved in 2024," said chief executive officer Octavio Alvídrez.

"Our full year guidance remains unchanged; silver production is down as anticipated, as we account for the impact of cessation of mining activities at the San Julián DOB, although we expect to see a stronger second half performance.

"Gold production is up on the same period last year, driven by a continued strong performance at Herradura, as well as the benefit of processing gold inventories accumulated in the previous period."

Alvídrez said that with those inventories now depleted, Fresnillo expected gold production to normalise in line with its guidance.

"Overall, our operations remain well-aligned with our plan, positioning us well to capitalise on stronger precious metals prices.

"Cost discipline remains a key focus, supported by a favourable Mexican peso-USD exchange rate.

"We are focused on sustaining our operational stability, maintaining our strong financial performance and delivering value to our stakeholders throughout 2025, with our core priority as always being the safety of our people and the well-being of our communities."

At 0817 BST, shares in Fresnillo were down 7.84% at 956.13p.

Reporting by Josh White for Sharecast.com.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.